Skip to main
ANNX

Annexon, Inc (ANNX) Stock Forecast & Price Target

Annexon, Inc (ANNX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Annexon is well-positioned in the biopharmaceutical industry, with a portfolio of potential blockbuster drugs targeting unmet medical needs in both autoimmune and neurodegenerative diseases. The company's strong leadership, led by CEO Douglas Love, and successful clinical trial results for its lead candidates, Vonaprument and Tinlarebant, indicate a high potential for success in the market. Additionally, the potential for significant sales from these drugs, especially in the under-served market for GA and GBS, is a strong indicator of the company's potential for financial growth.

Bears say

Annexon is a clinical-stage biopharmaceutical company with a pipeline of drug candidates targeting classical complement-mediated disorders, but their lead drug faces competition and may not be as effective as hoped. Investors are also wary of additional capital raises and the long timeline for profitability. There is potential for success in the market, but risks and challenges remain for Annexon.

Annexon, Inc (ANNX) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annexon, Inc (ANNX) Forecast

Analysts have given Annexon, Inc (ANNX) a Buy based on their latest research and market trends.

According to 7 analysts, Annexon, Inc (ANNX) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annexon, Inc (ANNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.